Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
US-10525029-B2 · Jan 7, 2020 · US
Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism
US11083702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11083702-B2 |
| Application number | US-201716094828-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2017 |
| Priority date | Apr 19, 2016 |
| Publication date | Aug 10, 2021 |
| Grant date | Aug 10, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of treating propionic acidemia (PA), methylmalonic acidemia (MMA) and fatty acid oxidation disorders are described. The methods include administering an anaplerotic agent that can directly enter the tricarboxylic acid cycle, such as a succinate derivative or pro-drug, for example trisuccinylglycerol (TSG). Methods of restoring tricarboxylic acid (TCA) cycle function in a cell deficient for propionyl-CoA carboxylase (PCC) or methylmalonyl-CoA mutase (MUT) by contacting the cell with a succinate derivative or pro-drug, such as TSG, are also described.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating propionic (PA) or methylmalonic acidemia (MMA) in a subject, comprising administering to the subject a therapeutically effective amount of trisuccinylglycerol
Assignees
Inventors
Classifications
Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety · CPC title
- A61K31/225Primary
Polycarboxylic acids · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11083702B2 cover?
- Methods of treating propionic acidemia (PA), methylmalonic acidemia (MMA) and fatty acid oxidation disorders are described. The methods include administering an anaplerotic agent that can directly enter the tricarboxylic acid cycle, such as a succinate derivative or pro-drug, for example trisuccinylglycerol (TSG). Methods of restoring tricarboxylic acid (TCA) cycle function in a cell deficient …
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification A61K31/225. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).